861
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Is cell therapy the answer for hematological malignancies?

ORCID Icon &
Pages 495-497 | Received 09 Nov 2017, Accepted 16 Mar 2018, Published online: 27 Mar 2018

References

  • Landoni E, Savoldo B. Treating hematological malignancies with cell therapy: where are we now? Expert Opin Biol Ther. 2017;5:1–11.
  • Tran E, Longo DL, Urba WJ. A milestone for CAR T cells. N Engl J Med. 2017 Dec 28;377(26):2593–2596.
  • Buechner J, Grupp SA, Maude SL, et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to the interim analysis. Haematologica. 2017;102:S476.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;28;377(26):2531–2544.
  • Grant M, Bollard CM. Developing T-cell therapies for lymphoma without receptor engineering. Blood Adv. 2017;8:2579–2590.
  • Klener P, Etrych T, Klener P. Biological therapy of hematologic malignancies: toward a chemotherapy-free era. Curr Med Chem. 2017;6. [ Epub ahead of print]. DOI:10.2174/0929867324666171006144725
  • Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015. 28. 125(22):3393–3400.
  • Jabbour E, Kantarjian H. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Adv. 2016. 27;1(3):260–264.
  • Kolb HJ. Hematopoietic stem cell transplantation and cellular therapy. HLA. 2017;89:267–277.
  • Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;19:pii: blood-2017-06-793869. [ Epub ahead of print]. DOI:10.1182/blood-2017-06-793869
  • Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2(1):567–572.
  • Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–1419.
  • Hartmann J, Schüßler-Lenz M, Bondanza A, et al. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183–1197.
  • Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017 28;377(26):2545–2554.
  • Chabannon C, Kuball J, Mcgrath E, et al. CAR-T cells: the narrow path between hope and bankruptcy? Bone Marrow Transplant. 2017;52(12):1588–1589.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.